Mammary cancer bone metastasis follow-up using multimodal small-animal MR and PET imaging

Journal of Nuclear Medicine

Volumn 54, Issue 6, 2013, Pages 944-952

  Doré Savard, Louis ^a   Barrière, David A ^a   Midavaine, Élora ^a   Bélanger, Danny ^a   Beaudet, Nicolas ^a   Tremblay, Luc ^a   Beaudoin, Jean François ^a   Turcotte, Eric E ^a   Lecomte, Roger ^a   Lepage, Martin ^a   Sarret, Philippe ^a  

^a UNIVERSITY OF SHERBROOKE   (Canada)

Author keywords

11C methionine; 18F FDG; 18F NaF; MR imaging; PET

Indexed keywords

FLUORODEOXYGLUCOSE F 18; GADOLINIUM PENTETATE; METHIONINE C 11; SODIUM FLUORIDE F 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BREAST CANCER; CONTRAST ENHANCEMENT; CONTROLLED STUDY; FOLLOW UP; IMAGE QUALITY; MALE; MICRO-COMPUTED TOMOGRAPHY; NON INVASIVE MEASUREMENT; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RAT; TUMOR GROWTH;

11C-METHIONINE; 18F-FDG; 18F-NAF; MR IMAGING; PET;

ANIMALS; BIOLOGICAL TRANSPORT; BONE NEOPLASMS; DISEASE PROGRESSION; FEMUR; FOLLOW-UP STUDIES; MAGNETIC RESONANCE IMAGING; MALE; MAMMARY NEOPLASMS, EXPERIMENTAL; POSITRON-EMISSION TOMOGRAPHY; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84878665041     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: 10.2967/jnumed.112.114215     Document Type: Article

References (42)

1. Coleman RE. Skeletal complications of malignancy. Cancer. 1997;80(8, suppl):1588-1594. (Pubitemid 27444031)
2. Cicek M, Oursler MJ. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev. 2006;25:635-644. (Pubitemid 46071868)
3. Costelloe CM, Rohren EM, Madewell JE, et al. Imaging bone metastases in breast cancer: techniques and recommendations for diagnosis. Lancet Oncol. 2009;10:606-614.
4. Robertson IJ, Hand F, Kell MR. FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast. 2011;20:491-494.
5. Histed SN, Lindenberg ML, Mena E, Türkbey B, Choyke PL, Kurdziel KA. Review of functional/anatomical imaging in oncology. Nucl Med Commun. 2012;33:349-361.
6. Houssami N, Costelloe CM. Imaging bone metastases in breast cancer: evidence on comparative test accuracy. Ann Oncol. 2012;23:834-843.
7. Tryciecky EW, Gottschalk A, Ludema K. Oncologic imaging: interactions of nuclear medicine with CT and MR imaging using the bone scan as a model. Semin Nucl Med. 1997;27:142-151. (Pubitemid 27194759)
8. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004;22:2942-2953. (Pubitemid 41079914)
9. Winkelmann CT, Figueroa SD, Rold TL, Volkert WA, Hoffman TJ. Microimaging characterization of a B16-F10 melanoma metastasis mouse model. Mol Imaging. 2006;5:105-114. (Pubitemid 44106145)
10. 18F-fluoride PET/CT. J Nucl Med. 2008;49:414-421.
11. 18F-NaF deposition. J Nucl Med. 2010;51:1826-1829.
12. 18F]fluoro-D-glucose. N Engl J Med. 1991;324:200.
13. Bäuerle T, Komljenovic D, Semmler W. Monitoring molecular, functional and morphologic aspects of bone metastases using non-invasive imaging. Curr Pharm Biotechnol. 2012;13:584-594.
14. Wehrl HF, Judenhofer MS, Wiehr S, Pichler BJ. Pre-clinical PET/MR: technological advances and new perspectives in biomedical research. Eur J Nucl Med Mol Imaging. 2009;36(suppl 1):S56-S68.
15. Doré-Savard L, Otis V, Belleville K, et al. Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain. PLoS ONE. 2010;5:e13774.
16. Bergeron M, Cadorette J, Beaudoin J-F, et al. Performance evaluation of the LabPET APD-based digital PET scanner. IEEE Trans Nucl Sci. 2009;56:10-16.
17. Bernier M, Lepage M, Lecomte R, Tremblay L, Doré-Savard L, Descoteaux M. Combining parallel multiresolution and PCA initialization for a fully automatic PET-MR imaging registration. Paper presented at: 19th Annual Meeting of the International Society of Magnetic Resonance in Medicine; May 7, 2001; Montreal, Canada.
18. Iida H, Miura S, Shoji Y, et al. Noninvasive quantitation of cerebral blood flow using oxygen-15-water and a dual-PET system. J Nucl Med. 1998;39:1789-1798. (Pubitemid 28473532)
19. 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45:695-700.
20. Doré-Savard L, Beaudet N, Tremblay L, Xiao Y, Lepage M, Sarret P. A microimaging study linking bone cancer pain with tumor growth and bone resorption in a rat model. Clin Exp Metastasis. 2013;30:225-236.
21. Hadjidakis DJ, Androulakis II. Bone remodeling. Ann N Y Acad Sci. 2006;1092:385-396. (Pubitemid 47092355)
22. Vassiliou V, Andreopoulos D, Frangos S, Tselis N, Giannopoulou E, Lutz S. Bone metastases: assessment of therapeutic response through radiological and nuclear medicine imaging modalities. Clin Oncol (R Coll Radiol). 2011;23:632-645.
23. Viel T, Talasila KM, Monfared P, et al. Analysis of the growth dynamics of angiogenesis-dependent and -independent experimental glioblastomas by multimodal small-animal PET and MR imaging. J Nucl Med. 2012;53:1135-1145.
24. Minn H, Clavo AC, Grénman R, Wahl RL. In vitro comparison of cell proliferation kinetics and uptake of tritiated fluorodeoxyglucose and L-methionine in squamous-cell carcinoma of the head and neck. J Nucl Med. 1995;36:252-258.
25. 11C-methionine PET assessment: patterns of integration in therapy planning. Eur J Nucl Med Mol Imaging. 2012;39:771-781.
26. Sadeghi N, Salmon I, Decaestecker C, et al. Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR. 2007;28:455-461. (Pubitemid 46481882)
27. 11Cmethionine PET scans in patients with newly progressive metastatic prostate cancer. J Nucl Med. 2002;43:46-55.
28. 11C-methionine PET/CT - initial experience. Radiology. 2007;242:498-508.
29. Kubota R, Kubota K, Yamada S, et al. Methionine uptake by tumor tissue: a microautoradiographic comparison with FDG. J Nucl Med. 1995;36:484-492.
30. 11C-L-methionine positron emission tomography in the clinical management of cerebral gliomas. Mol Imaging Biol. 2008;10:1-18.
31. Caroli P, Nanni C, Rubello D, Alavi A, Fanti S. Non-FDG PET in the practice of oncology. Indian J Cancer. 2010;47:120-125.
32. Lindholm P, Lapela M, Någren K, Lehikoinen P, Minn H, Jyrkkiö S. Preliminary study of carbon-11 methionine PET in the evaluation of early response to therapy in advanced breast cancer. Nucl Med Commun. 2009;30:30-36.
33. 18F]-fluoroestradiol quantitative PET imaging to differentiate ER1 and ERa-knockdown breast tumors in mice. Nucl Med Biol. 2012;39:57-64.
34. Biganzoli L, Wildiers H, Oakman C, et al. Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol. 2012;13:e148-e160.
35. Kelloff GJ, Bast RC, Coffey DS, et al. Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue. Clin Cancer Res. 2004;10:3881-3884. (Pubitemid 38697624)
36. 18F-FDG PET in malignant tumors. J Nucl Med. 2008;49:1804-1808.
37. Krak NC, Boellaard R, Hoekstra OS, Twisk JWR, Hoekstra CJ, Lammertsma AA. Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial. Eur J Nucl Med Mol Imaging. 2005;32:294-301. (Pubitemid 40562120)
38. Rosario BL, Weissfeld LA, Laymon CM, et al. Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET. Neuroimage. 2011;55:933-941.
39. Yin JJ, Zhang L, Munasinghe J, Linnoila RI, Kelly K. Cediranib/AZD2171 inhibits bone and brain metastasis in a preclinical model of advanced prostate cancer. Cancer Res. 2010;70:8662-8673.
40. Bä uerle T, Merz M, Komljenovic D, Zwick S, Semmler W. Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal in vivo study. Clin Cancer Res. 2010;16:3215-3225.
41. 68Ga-NOTAVEGF 121 for the imaging of VEGF receptor expression in U87MG tumor xenograft models. Eur J Nucl Med Mol Imaging. 2013;40:198-206.
42. 61Cu- labeled lysine-tagged VEGF(121). Mol Pharm. November 16, 2012 [Epub ahead of print].